Home › NDC Lookup › RxCUI directory › RxCUI 643066

Efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet — RxCUI 643066

RxNorm drug concept · Semantic clinical drug
RxCUI 643066 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI643066
Official nameEfavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asefavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet
FDA products mapped7
Package NDCs mapped8
Reported Medicaid activity (SDUD)4,121 prescriptions · 24 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Emtricitabine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Emtricitabine doesn't cure HIV, but it's an important part of keeping the virus under control. It works by blocking an enzyme HIV needs to make copies of itself. When it's used alo...
  • What exactly does emtricitabine do — does it cure HIV?
  • Please don't stop without talking to your doctor first. If you also have hepatitis B, stopping emtricitabine can trigger a sudden, severe flare of hepatitis B — sometimes serious e...
  • Can I stop taking emtricitabine if I feel fine or if I also have hepatitis B?
📖 Read our full Emtricitabine guide →

🕸️ Concept Web — How Efavirenz 600 MG / emtricitabine 200 MG / tenofo... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet RxCUI 643066

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Efavirenz 195085
    • Emtricitabine 276237
    • Tenofovir disoproxil 300195
    • Efavirenz / emtricitabine / tenofovir disoproxil 1007761
    • Tenofovir disoproxil fumarate 322248
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Atripla 643067
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Efavirenz / emtricitabine / tenofovir disoproxil Oral Tablet 643065
    • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Oral Tablet 2646687
    • Efavirenz / emtricitabine / tenofovir disoproxil Oral Product 1161286
    • Efavirenz / emtricitabine / tenofovir disoproxil Pill 1161287
    • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Oral Product 2659192
    • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Pill 2662147
    • Efavirenz / emtricitabine / tenofovir disoproxil Oral Tablet [Atripla] 643069
    • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Oral Tablet [Atripla] 2658782
    • +5 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Efavirenz 600 MG 350652
    • Emtricitabine 200 MG 406016
    • Tenofovir disoproxil fumarate 300 MG 393334
    • Efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Atripla] 643070
    • Efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG [Atripla] 643068

Showing up to 8 concepts per family — 19 of 24 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Efavirenz 600 MG SCDC · 350652
  • Emtricitabine 200 MG SCDC · 406016
  • Tenofovir disoproxil fumarate 300 MG SCDC · 393334
  • Efavirenz / emtricitabine / tenofovir disoproxil Oral Tablet SCDF · 643065
  • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Oral Tablet SCDFP · 2646687
  • Efavirenz / emtricitabine / tenofovir disoproxil Oral Product SCDG · 1161286
  • Efavirenz / emtricitabine / tenofovir disoproxil Pill SCDG · 1161287
  • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Oral Product SCDGP · 2659192
  • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Pill SCDGP · 2662147

Brand-Name Concepts

  • Efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Atripla] SBD · 643070
  • Efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG [Atripla] SBDC · 643068
  • Efavirenz / emtricitabine / tenofovir disoproxil Oral Tablet [Atripla] SBDF · 643069
  • Efavirenz / emtricitabine / tenofovir disoproxil fumarate Oral Tablet [Atripla] SBDFP · 2658782
  • Atripla Oral Product SBDG · 1172891
  • Atripla Pill SBDG · 1172892
  • Atripla BN · 643067

📦 FDA Products & Package NDCs

7 products · 8 package NDCs
8 package NDCs map to RxCUI 643066 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00093-5234-56 30 TABLET, FILM COATED in 1 BOTTLE (0093-5234-56) Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Teva Pharmaceuticals USA, Inc. 2020-10-01
31722-0736-30 30 TABLET, FILM COATED in 1 BOTTLE (31722-736-30) Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Camber Pharmaceuticals, Inc. 2022-01-24
33342-0138-07 30 TABLET, FILM COATED in 1 BOTTLE (33342-138-07) Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Macleods Pharmaceuticals Limited 2021-09-13
42385-0915-30 30 TABLET, FILM COATED in 1 BOTTLE (42385-915-30) Efavirenz, emtricitabine and tenofovir disoproxil fumarate Laurus Labs Limited 2021-12-22
42385-0915-90 90 TABLET, FILM COATED in 1 BOTTLE (42385-915-90) Efavirenz, emtricitabine and tenofovir disoproxil fumarate Laurus Labs Limited 2021-12-22
65862-0497-30 30 TABLET, FILM COATED in 1 BOTTLE (65862-497-30) Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate Aurobindo Pharma Limited 2021-03-30
69097-0210-02 30 TABLET, FILM COATED in 1 BOTTLE (69097-210-02) efavirenz, emtricitabine and tenofovir disoproxil fumarate Cipla USA Inc. 2021-03-30
72162-2565-03 30 TABLET, FILM COATED in 1 BOTTLE (72162-2565-3) Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate Bryant Ranch Prepack 2025-11-04
Observed labelers: Laurus Labs Limited (2) · Aurobindo Pharma Limited (1) · Bryant Ranch Prepack (1) · Camber Pharmaceuticals, Inc. (1) · Cipla USA Inc. (1) · Macleods Pharmaceuticals Limited (1) · +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$1.1738
Range $1.1738–$1.1738 · middle 50% $1.1738–$1.1738 · 6 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.